The rising cost of medicines to the NHS: what’s the story?

This content relates to the following topics:

Medicines are a vital part of modern health care. The question of how to give patients access to them in a way that the NHS can afford has exercised policy-makers and politicians for many years.

In this briefing, we look at how much the health service spends in total on medicines, both generics and branded medicines, based on publicly available data. In recent years, spending on branded medicines has been constrained by the Pharmaceutical Price Regulation Scheme a new instalment of which is currently under negotiation. We also explore policies used to try to control growth in costs and the choices policy-makers are likely to face in the future.

Key messages

  • Estimated total NHS spending on medicines in England has grown from £13 billion in 2010/11 to £17.4 billion in 2016/17 – an average growth of around 5 per cent a year. These figures are uncertain due to gaps in data, but the rate of increase is substantially faster than for the total NHS budget over the same period.
  • Much of the recent growth in medicines spending has been in the hospital sector, where estimated costs have grown at around 12 per cent a year on average since 2010/11. Today hospitals account for nearly half of total NHS spending on medicines. 
  • In primary care, spending growth has been much lower. Although the volume of prescription items provided to patients increased by almost half in the decade to 2016 (to 1.1 billion items), this was offset by a reduction of nearly a quarter in the average cost per prescription item (to £8.34).
  • Policy on medicines in England aims to balance the competing goals of giving patients prompt access to effective treatments, incentivising the pharmaceutical sector to develop new products, and ensuring that expenditure on medicines is affordable for the NHS. Today it is becoming harder to balance these objectives.
  • Over time the NHS has used a number of policies to promote value for money in spending on medicines, such as encouraging the widespread use of cheaper generic drugs. Opportunities to generate additional value remain, such as increasing the uptake of biosimilars (which resemble generics for biological products). But with growth in spending on medicines outstripping growth in funding, policy-makers have recently sought to exert greater control over medicines expenditure – for instance with the introduction of a controversial budget impact test for new products that will cost more than £20 million a year to provide.
  • Given the founding principles of the NHS, policy options that are available in some other advanced health care systems, such as significantly increasing user charges for medicines, would be politically challenging to implement in England.
  • Without a new funding settlement for the NHS, policy-makers are likely to face increasingly difficult choices. There is a risk of returning to the position of the 1990s, when funding pressures led to widespread concern about patients’ access to medicines.

Comments

SHIRLEY HARDING

Position
Retired nurse,
Comment date
19 August 2020

If a drug is cheaper to buy over the counter and not requiring a 'script' then the patient should buy it ... many items should not be allowed on script, e.g. hay fever tabs, head lice treatments, all the common issues which can be managed by a visit to a pharmacy.
Where a GP is changing a medication, issue a smaller amount, all too often a months supply is issued, then changed when the patient has problems with the medication. If suitable and suitable for ongoing care, the patient can order online.
GP's should check when the patient last ordered, ensure the patent is taking the medication / treatment before 'signing off' more scripts. Medication reviews are often just a quick look down the prescription list and continue to prescribe, who ever asked the patient if a treatment is working, of if indeed the patient still requires that treatment?
So much money is wasted due to lack of medication reviews and issuing large amounts of new drugs fro a first time.
Perhaps GP's should should refer patients back to a pharmacy if an ailment can be managed there.
It is not rocket science, just plain old common sense, but it seems the NHS is afraid to do anything that just might upset the patient?

amanda Evans

Position
Pharmacist,
Comment date
09 July 2019

WE can't just accept medicines back in the pharmacy because theres no guarantee that they've been stored correctly. They may have been kept in a hot suitcase, or a freezer, or in a damp cupboard- and any of these storage issues might render the contents unusable.
There may even be malicious deliberate tampering - there's just no way of knowing.
Patient safety and medication efficacy are the pharmacist's primary concern here- so potentially unstable medicines cannot be just placed back into the dispensary- even though , I absolutely agree, its a heartbreaking waste of resources.

Moira conway

Position
Retired,
Comment date
30 May 2019

Yes true! I have medicines I did not use. The were not over prescribed but were changed. I took them back to the chemist who said they couldn’t re prescribe them as they may not be safe. Even though they are I. Sealed package -bubble package.
Friend are hanging on to them in,
Can we check then and put them back on the shelf at the chemist.

Derek Land

Position
Retired biochemist,
Organisation
Norfolk Council on Ageing/Norfolk Family Carers
Comment date
27 April 2018

Much has been said about maintenance of well-being/prevention of loss of wellbeing but little appears to be being positively done. There is a huge waste in unused prescriptions, so some emphasis is required to address amounts prescribed and re-issue of prescriptions without adequate review of need.

Add your comment